The tenth batch of national centralized procurement for Puli Pharmaceutical's gadolinium gluconate i

The tenth batch of national centralized procurement for Puli Pharmaceutical's gadolinium gluconate injection and posaconazole injection has won both bids! On December twelve, two thousand twenty-four, Puli Pharmaceutical won the bid for gadolinium gluconate injection (trade name: Puli Yingxian) and posaconazole injection (trade name: Puliposa) in the tenth batch of national centralized drug procurement! The winning specification for the centralized procurement of Puli Pharmaceutical's Puli Imaging Gadolinate Glucosamine Injection is fifteenml: five.six thousand five hundred and thirty-fiveg. Puli Yingxian Gadot Acid Glucosamine Injection is a macrocyclic ionic magnetic resonance contrast agent produced by Hainan Puli Pharmaceutical Co., Ltd. Puli Pharmaceutical's gadolinium gluconate injection has been approved by the US FDA in June two thousand twenty-four, and other countries are currently applying for it. This variety is a Sino US dual reporting variety, sharing a production line with the domestic and American markets, with the same quality standards and product quality, and stable and reliable quality. Puli Pharmaceutical's Gadetinic Acid Glucosamine Injection has been approved by the US FDA. Gadetinic Acid Glucosamine Injection is an integrated product of Puli Pharmaceutical's raw material preparation, and its raw materials come from Anhui Puli Pharmaceutical Co., Ltd., a subsidiary of Hainan Puli Pharmaceutical Co., Ltd. As an integrated variety of raw material formulations, Puli Pharmaceutical's gadolinium gluconate injection is not restricted by the raw material drug market and can stably guarantee clinical supply. The registration content of Puli Pharmaceutical's gadolinium citrate glucosamine raw materials includes five approved specifications for Puli Imaging gadolinium citrate glucosamine injection in China, namely: fiveml: one.eight thousand eight hundred and forty-fiveg, tenml: three.seven hundred and sixty-nineg, fifteenml: five.six thousand five hundred and thirty-fiveg, twentyml: seven.five hundred and thirty-eightg, one hundredml: thirty-seven.sixty-nineg (calculated based on gadolinium citrate glucosamine). The specifications are complete and consistent with the approved specifications of the original Guebert in the United States, which can fully meet the needs of different clinical patients' MRI enhanced examination projects. The winning bid specification for the centralized procurement of two Prispoxaconazole Injection by Prispoxaconazole Pharmaceutical is sixteen.sevenml: zero.threeg. Posaconazole is a new generation of triazole antifungal drugs. Compared with other products of the same type, it has strong antibacterial activity, wider antibacterial spectrum, and higher safety. It is recommended by many authoritative guidelines at home and abroad as a first-line drug for the prevention and treatment of fungal infections. Posaconazole injection has been included in the two thousand twenty-four version of the national medical insurance catalog and is classified as a Class B medical insurance product. In addition, in June two thousand twenty-four, the National Medical Products Administration issued a notice expanding its indications to children aged two and above, with clear usage and dosage for children. It can be foreseen that the clinical application of posaconazole injection will inevitably be further expanded. The revised content of indications, usage, and dosage of Posaconazole injection for children. Prinosaconazole injection is a dual reporting product in China and the United States, and is currently under review in the US market. In addition to the US, Prinosaconazole Pharmaceutical will also expand its presence in countries such as the UK, Australia, and New Zealand. Since the national pilot program for centralized procurement was launched at the end of two thousand eighteen, centralized procurement of pharmaceuticals has gradually become an important mode of purchasing drugs and medical consumables, benefiting more patients. Puli Pharmaceutical also responds to national policies, and currently has multiple products that have achieved centralized procurement and won bids, covering multiple treatment fields. Puli